Inhibitory Antibodies

A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.

The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.

After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.

Targetmol provides xnum monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.

Cat. No.	Product name	CAS No.	Purity	Chemical Structure
T9923	Nimotuzumab	828933-51-3	95.00%
T9923	Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).
T78337	Mouse IgG2a kappa, Isotype Control		98%	Mouse IgG2a kappa, Isotype Control
T78337	Mouse IgG2a kappa, Isotype Control is an isotype antibody to murine-derived IIgG2a kappa antibody.			Mouse IgG2a kappa, Isotype Control
T36653	Anti-SARS-80R mAb		98%	Anti-SARS-80R mAb
T36653	Anti-SARS-80R mAb (SARS-80R) is a human IgG1 monoclonal antibody that is derived from CHO cells. Its main function is to selectively bind to the Spike (S1) prote...			Anti-SARS-80R mAb
T36654	Anti-SARS-CoV-2 Spike mAb (CR3022)		98%	Anti-SARS-CoV-2 Spike mAb (CR3022)
T36654	Anti-SARS-CoV-2 Spike mAb (CR3022) is a human monoclonal IgG1 antibody derived from CHO cells. It specifically targets the S1 domain of the Spike protein in both...			Anti-SARS-CoV-2 Spike mAb (CR3022)
T36651	Anti-MERS-2E6 mAb		98%	Anti-MERS-2E6 mAb
T36651	Anti-MERS-2E6 mAb (MERS-2E6), a human IgG1 neutralizing antibody, is expressed in CHO cells. It effectively competes with the virus Spike protein for binding to ...			Anti-MERS-2E6 mAb
T36655	Anti-Spike-RBD mAb		98%	Anti-Spike-RBD mAb
T36655	Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of spike protein and ACE2 is a potential therapeutic approach f...			Anti-Spike-RBD mAb
T9922	Matuzumab	339186-68-4	98%	Matuzumab
T9922	Matuzumab is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR frequently associated with the growth of blood vessels in ...			Matuzumab
T35389	Sarilumab (anti-IL-6Rα)		98%	Sarilumab (anti-IL-6Rα)
T35389	Sarilumab (anti-IL-6Rα) is a useful organic compound for research related to life sciences and the catalog number is T35389.			Sarilumab (anti-IL-6Rα)
T36656	Anti-Spike-RBD Single Domain mAb		98%	Anti-Spike-RBD Single Domain mAb
T36656	The Anti-Spike-RBD Single Domain mAb is a monoclonal antibody derived from CHO cells in Alpaca. It is composed of VHH-huFc and exhibits a strong affinity for the...			Anti-Spike-RBD Single Domain mAb
T12706	Reslizumab	241473-69-8	98%
T12706	Reslizumab is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma.
T9931	Meplazumab	2413715-21-4	98%	meplazumab
T9931	meplazumab is a humanized anti-CD147 antibody, as add-on therapy in patients with COVID-19 pneumonia.			meplazumab
T36652	Anti-MERS-3A1 mAb		98%	Anti-MERS-3A1 mAb
T36652	Anti-MERS-3A1 mAb (MERS-3A1) is a high-affinity human monoclonal IgG1 antibody derived from CHO cells. It effectively inhibits the interaction between the MERS-C...			Anti-MERS-3A1 mAb
T35396	Spartalizumab (anti-PD-1)		98%	Spartalizumab (anti-PD-1)
T35396	Spartalizumab (anti-PD-1) is a useful organic compound for research related to life sciences and the catalog number is T35396.			Spartalizumab (anti-PD-1)
T76559	Survodutide	2805997-46-8	99.83%
T76559	Survodutide (BI 456906) is a dual agonist of glucagon and glucagon-like peptide 1 (GLP-1) receptor (GLP Receptor) that reduces body weight in HbA1c16 diabetes.
T9908	Pembrolizumab	1374853-91-4	99.70%	Pembrolizumab
T9908	Pembrolizumab is a humanized monoclonal antibody inhibiting the PD-1 receptor and the first in the class of agents called the HER2 dimerization inhibitors that i...			Pembrolizumab
T9921	Infliximab	170277-31-3	99.70%
T9921	Infliximab is a humanized antibody against tumor necrosis factor α TNF-α) that is used in the treatment of Crohn's disease and rheumatoid arthritis.
T9913	Ustekinumab	815610-63-0	99.70%
T9913	Ustekinumab is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody.
T9906	Ipilimumab	477202-00-9	99.60%
T9906	Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibit...
T9911	Tocilizumab	375823-41-9	99.50%
T9911	Tocilizumab (anti-IL-6R) is a humanized monoclonal antibody that binds to the interleukin-6 receptor
T9930	Secukinumab	875356-43-7	99.10%	Secukinumab
T9930	Secukinumab is a fully humanized monoclonal anti-IL-17A antibody and the first in its class to be approved by the US Food and Drug Administration for the treatme...			Secukinumab